Difenidramina 50 mg/ml - ampola 1 ml e seu processo de padronização no âmbito do Distrito Federal
DOI:
https://doi.org/10.51208/saudeinovacao.v2i1.56Abstract
The drug called diphenhydramine 50 mg/ml - 1 ml ampoule is indicated for the prevention and treatment of allergic reactions related to blood or plasma transfusion and as an adjuvant to epinephrine in anaphylaxis. Standardization of this drug was requested in the List of Medicines of the Federal District (REME-DF), together with the drug cimetidine 150 mg/ml ampoule 2 ml, with indication of pre-chemotherapy histamine blockade (pre-QT). For this, a health technology assessment tool was used, through a bibliographic survey in Medline databases via Pubmed; Embase, Cochrane Library and Biblioteca Virtual em Saúde - BVS. In view of this request, received by the CCFT, an analysis was carried out considering up-to-date literature on this product. A total of 655 articles were found, 7 of which were included in this analysis. In conclusion, with a favorable safety and efficacy assessment, this drug was standardized within the Federal District.
References
CRISTÁLIA. https://consultas.anvisa.gov.br/#/bulario/q/?nomeProduto=DIFENIDRIN Acesso em: 24.11.2021
Sato A, Sakashita A, Taguchi S. [Hypersensitivity reactions to cancer chemotherapeutic agents]. Gan To Kagaku Ryoho. 2003 Jun;30(6):793-800. Japanese. PMID: 12852346.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche P, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009 Jul;6(7):e1000100.
Alessandro Gozzetti; Francesca Bacchiarri; Francesca Di Martino; Cristiana Caffarelli; Anna Sicuranza; Elisabetta Zappone; Donatella Raspadori; Marzia Defina; Emanuele Cencini; Vincenzo Sammartano; Bianca Mecacci; Monica Bocchia. LONG TERM SAFETY AND EFFICACY OF DARATUMUMAB RAPID INTRAVENOUS INFUSION (90 MINUTES) AFTER THE THIRD DOSE IN MULTIPLE MYELOMA PATIENTS. ABSTRACT ONLY| VOLUME 19, ISSUE 10, SUPPLEMENT , E147-E148, OCTOBER 01, 2019
de Castro Baccarin AL, Irene MN, de Iracema Gomes Cubero D, Luz AS, Castro SN, Sordi R, Móz LES, Del Giglio A. The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients. Support Care Cancer. 2019 Mar;27(3):927-931. doi: 10.1007/s00520-018-4381-0. Epub 2018 Aug 1. PMID: 30069696
Modelevsky L, Tizon R, Reiss SN, Smith M, Garonce R, Kaley T. Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma. CNS Oncol. 2018 Jul 1;7(3):CNS19. doi: 10.2217/cns-2018-0001. Epub 2018 Sep 17. PMID: 30221993; PMCID: PMC6200062.
Parisi, M.; Del Fabro, V.; Martino, E.; Calafiore, V.; Sapienza, G.; Leotta, V.; Parrinello, N.L.; Triolo, A.; Romano, A.; Conticello, C.; Di Raimondo, F.; Daratumumab monotherapy in real life community setting of refractory myeloma patients: Comfortable management of infusion-related reactions at the first infusion. Haematologica - Volume 103, Issue 0, pp. S84 - published 2018-01-01
Moreau, P.; Rabin, N.; Plesner, T.; Weisel, K.; Sonneveld, P.; Mateos, M-V.; Schecter, J.M.; Amin, H.; Trivedi, S.; Dimopoulos, M.A.; Management of infusion-related reactions (IRRs) in patients (pts) receiving daratumumab plus standard of care for the treatment of multiple myeloma (MM) in the phase 3 studies CASTOR and POLLUX. Ann. Oncol. - Volume 28, Issue 0, pp. v356-v357 - published 2017-01-01
Martin, T.G.; Mannis, G.N.; Chari, A.; Munster, P.; Campana, F.; Hui, A.-M.; Wolf, J.L.; Phase Ib study of isatuximab and carfilzomib in relapse and refractory multiple myeloma. Blood - Volume 128, Issue 22, pp. - published 2016-01-01
Durham CG; Thotakura D; Sager L; Foster J; Herrington JD; Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners - Volume 25, Issue 6, pp. 1396-1401 - published 2019-09-01
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Juliana Carvalho Rocha Alves da Silva, Marcus Tulio Batista Silva, Walleska Fidelis Gomes Borges
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Os autores declaram aceitar a política de direito autoral praticada pela revista. A submissão de originais para a Revista Saúde e Inovação implica na transferência, pelos autores, dos direitos de publicação impressa e digital. Os direitos autorais para os artigos publicados nesta revista são do autor, com direitos da revista sobre a primeira publicação. Os autores somente poderão utilizar os mesmos resultados em outras publicações indicando claramente a Revista Saúde e Inovação como o meio da publicação original. Em virtude de tratar-se de um periódico de acesso aberto, é permitido o uso gratuito dos artigos, principalmente em aplicações educacionais e científicas, desde que citada a fonte. A Revista Saúde e Inovação adota a licença Creative Commons Atribuição 4.0 Internacional (CC BY 4.0): https://creativecommons.org/licenses/by/4.0/deed.pt_BR
A 